Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders

Date : 09/27/2019 @ 6:32PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.57  0.14 (0.36%) @ 9:11PM
After Hours
Last Trade
Last $ 38.57 ◊ 0.00 (0.00%)

Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Roche Holding (QX) Charts.

By Michael Dabaie

 

Roche Holding AG's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.

GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessels.

This approval is the first pediatric indication for Rituxan, Genentech said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 27, 2019 14:17 ET (18:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.